Post-Operative Articles & Analysis

Based on data from early animal studies, Probudur has indicated post-operative control for up to 96 hours, which is 24 hours longer than the leading product on the market. If we are able to demonstrate a successful Phase III clinical trial, we believe Probudur may represent the first long acting local anesthetic with an opioid sparing label. ...

By Virpax Pharmaceuticals

On Sunday, 3rd July, Mike Callaghan – Head of Business Development at GPT Waste Management Ltd completed the Windermere Triathlon in a bid to raise funds for The Joshua Wilson Brain Tumour Charity. The Windermere Triathlon is in no way for the faint hearted. It is a challenge only undertaken by those strong enough, and brave enough to believe they can reach the finish line. Starting with ...

By Lightsource BP

Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced that the Company’s management will be participating in the 2022 Jeffries Innovation inMental Health Summit. Bexson’s Chief Executive Officer, Gregg Peterson, and Chief Scientific Officer, Jeffrey Becker, are ...

By Bexson Biomedical

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative ...

By Merck & Co., Inc.,

Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it had made equity grants to four new employees under its 2021 Inducement Plan. On May 4, 2022, the Company’s Compensation Committee granted options to four new non-executive employees covering an aggregate of 140,000 shares ...

By Palisade Bio

Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announced treatment of the first patients in its first-in-human study for ACTISEAL®, its Liver and Pancreas Sealant Patch. The ‘SHIELDS’ trial is a prospective, multicenter study, evaluating the safety and performance of ACTISEAL® in reducing fluid ...

By Regenity

Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions, today announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application No. 17/546,880 filed on December 9, 2021 and titled Complexing Agent Salt Formulations of Pharmaceutical Compounds. Bexson’s ...

By Bexson Biomedical

TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption application for its vascular sealant. The approval is the most recent validation of TISSIUM’s efforts to develop a unique platform of proprietary ...

By TISSIUM

Dr. Matthew J. Kirsch of Rochester, MN, has been selected by Sonex Health, Inc. as a national Center of Excellence physician for carpal tunnel release (CTR) using the SX-One MicroKnife® and real-time ultrasound guidance. Since adopting the technique more than three years ago, Dr. Kirsch has helped hundreds of patients enjoy rapid recovery. A small incision in the wrist is typically closed ...

By Sonex Health Inc.

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces that they will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022, and at Biotech Showcase taking place January 10-12, 2022. The Palisade Bio management team also will be hosting investor ...

By Palisade Bio

Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) announces the appointment of the internationally recognized Interventional Cardiologist, Dr Chris Meduri MD MPH, as its Chief Medical Officer (CMO). Dr Meduri is a recognized leader in the field of valvular heart disease, serving as the national principle investigator of several valve trials and on numerous steering committees. He has ...

By Anteris Technologies Limited

BioQ Pharma Incorporated, a specialty pharmaceutical company, today announced that it has entered into a Development, Supply, Distribution Agreement with Avanos Medical, Inc. (NYSE: AVNS, “Avanos”). Under the agreement, the parties will work together to obtain appropriate regulatory approvals and commercialize self-contained, infusible, non-opioid post-operative pain pharmaceutical ...

By BioQ Pharma

ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity Approval for post-operative respiratory depression expected in 2026 and community drug overdose thereafter ENA-001 works peripherally by inhibiting Big Potassium (BK) ion channels in the carotid bodies, which are located in the neck. By inhibiting these channels, ...

By Enalare Therapeutics Inc.

U.S. Senator Chris Murphy (D-Conn.) announced that BioWave, based in Norwalk, CT, has been named April’s “Innovator of the Month.” BioWave is a patented smarter pain blocking technology that provides immediate, deep, long lasting relief of severe pain. BioWave devices deliver therapeutic electrical signals through skin directly to pain nerves in deep tissue to prevent pain ...

By BioWave Corporation

IlluminOss Medical, a medical device company focused on minimally invasive orthopedic fracture repair, today announced that it has received expanded U.S. Food and Drug Administration (FDA 510k) clearance for its Photodynamic Bone Stabilization System for treatment of fractures of the pelvis, clavicle, and the small bones of the hands and feet: metacarpals, metatarsals, and phalanges. The ...

By IlluminOss Medical, Inc.

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma. ITM-31 is a carbonic anhydrase XII (CA XII)-specific antibody Fab fragment developed by Helmholtz Munich and coupled with ITM's ...

By ITM Isotope Technologies Munich SE

Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced an oral presentation of data from its phase 2a study ALK6019-201 in mild-to-moderate Alzheimer’s Disease at the 12th Clinical Trials on Alzheimer’s Disease from December 4 – 7, 2019 in San Diego. Presentation details ...

By Alkahest, Inc.

Aatru Medical, LLC ("Aatru") today announced U.S. Food and Drug Administration (FDA) 510(k) Class II clearance of the NPSIMS™ Negative Pressure Surgical Incision Management System. The NPSIMS utilizes an innovative mode-of-action that eliminates the expensive electromechanical pump, battery, and electronics found in most other negative pressure wound therapy (NPWT) systems being deployed ...

By Aatru Medical, LLC

Ondine Biomedical Inc. (LON: OBI), has recruited the final patient to its nasal photodisinfection exploratory Phase 2 trial. The trial is evaluating how effectively Ondine’s nasal photodisinfection technology eradicates pathogens – specifically Staphylococcus aureus – in the nose. The single-center, BENEFIT-aPDT open-label study is being carried out at HCA Healthcare’s ...

By Ondine Biomedical Inc

Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announced treatment of the first patient in its ENCASE II clinical trial for LIQOSEAL. LIQOSEAL is an easy-to-use, synthetic dura sealant patch indicated for use as an adjunct to standard methods of cranial dural repair, to provide watertight closure of the dura mater and ...

By Regenity